Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1996

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Safety of combined oral contraceptive pills [letter]

AUTHORS

Plu-Bureau G; Amiral J; Guize L; Scarabin PY

SOURCE

Lancet. 1996 Feb 24;347(9000):549.

ABSTRACT

A case-control study has shown similar results to the three studies published in The Lancet. Besides a raised VTE

risk, this study suggested a decreased risk of myocardial infarction with the use of third-generation OCs compared

with second-generation OCs. Combined OCs affect clotting factors, creating a state of hypercoagulability that, to a

large extent, seems counterbalanced by increased fibrinolytic activity. We have shown an alteration of blood

coagulation and fibrinolysis in OC users within the 30-50 mcg estrogen range. In addition, our data showed no

substantial change in markers of thrombogenic risk when estrogen content of combined OC was decreased from 50

to 30 mcg. The effect of third-generation OCs on hemostatic factors is not well documented. Any changes in the

hemostatic system might partly account for these epidemiological results. We have investigated the associations

between use of OC containing low-dose of ethinyl estradiol (<or= 35 mcg) and the hemostatic system in a cross-

sectional study in premenopausal women. 188 consecutive healthy White women aged 25-55 years were recruited

from a health center (JPC) in Paris. 18 women used OCs containing new progestagens (desogestrel, gestodene, or

norgestimate) and 22 women used OCs containing other progestagens. Our results show a better lipidic profile of

the third-generation progestagens with a significant increase in HDL-cholesterol than in non-users. The factor VIIc

level was significantly higher in the third-generation OC group than in the other progestagen group. This difference

was partly explained by a rise in activated factor VII (factor VIIa). A similar trend was observed with D-dimers. With

respect to the fibrinolytic system, a decrease in both plasminogen activator inhibitor (PAI)-1 activity and tissue

plasminogen activator antigen (t-PA:Ag) levels in OC users was consistent with an increased fibrinolytic potential,

which was more pronounced in new OC preparations. Our findings suggest that new progestagens might induce a

favorable lipid profile but may also result in activation of coagulation, which can be counterbalanced by increased

fibrinolytic activity. These results are consistent with an excess risk of VTE as well as potential decreased risk of

myocardial infarction in women taking third-generation OCs. (PubHealth.info Document ID: CONT2T 2091-06)

PubHealth.info NOTE: The author(s) of this article titled, "Safety of combined oral contraceptive pills [letter]", is(are)

Plu-Bureau G; Amiral J; Guize L; Scarabin PY. The source of this article is "Lancet. 1996 Feb 24;347(9000):549.".

This article was published in 1996 in English language(s). (PubHealth.info® Document ID: CONT2T 2091-06. All

rights reserved with PubHealth.info) PIN: 7091

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.